We are live on ! Find out more
NKTR icon

Nektar Therapeutics
NKTR

230 hedge funds and large institutions have $561M invested in Nektar Therapeutics in 2022 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 70 increasing their positions, 74 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

814% more call options, than puts

Call options by funds: $2M | Put options by funds: $219K

20% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 25

1% more funds holding

Funds holding: 227 → 230 (+3)

0.3% less ownership

Funds ownership: 6.53% → 6.24% (-0.3%)

5% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 74

19% less capital invested

Capital invested by funds: $693M → $561M (-$131M)

Holders
230
Holders Change
+3
Holders Change %
+1.32%
% of All Funds
3.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
30
Increased
70
Reduced
74
Closed
25
Calls
$2M
Puts
$219K
Net Calls
+$1.78M
Net Calls Change
-$1.41M

Top Buyers

1
BlackRock
BlackRock
New York
+$13.8M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$10.2M
3
Northern Trust
Northern Trust
Illinois
+$3.87M
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$3.21M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$2.89M

Top Sellers

1
First Trust Advisors
First Trust Advisors
Illinois
-$29.8M
2
MC
Maverick Capital
Texas
-$12.2M
3
GPP
Great Point Partners
Connecticut
-$10.7M
4
AllianceBernstein
AllianceBernstein
Tennessee
-$4.33M
5
State Street
State Street
Massachusetts
-$3.46M
Name Holding Trade Value Shares
Change 		Change in
Stake
Allspring Global Investments
76
Allspring Global Investments
North Carolina
$424K -$36.6K -615 -7%
SOADOR
77
State of Alaska Department of Revenue
Alaska
$415K -$44.3K -744 -8%
BC
78
Birchview Capital
Vermont
$410K – – –
New York State Common Retirement Fund
79
New York State Common Retirement Fund
New York
$369K +$52.6K +884 +13%
ELI
80
Empire Life Investments
Ontario, Canada
$327K +$14.2K +238 +4%
BNP Paribas Financial Markets
81
BNP Paribas Financial Markets
France
$323K -$847K -14,231 -68%
AIG
82
American International Group
New York
$319K +$4.64K +78 +1%
MIM
83
MetLife Investment Management
New Jersey
$304K – – –
NYLIM
84
New York Life Investment Management
New York
$299K +$27.2K +457 +8%
LSERS
85
Louisiana State Employees Retirement System
Louisiana
$286K -$2.38K -40 -0.7%
AB
86
Amalgamated Bank
New York
$266K +$11.5K +194 +4%
Russell Investments Group
87
Russell Investments Group
United Kingdom
$264K +$316K +5,307 +2,288%
HSBC Holdings
88
HSBC Holdings
United Kingdom
$263K +$150K +2,521 +88%
Deutsche Bank
89
Deutsche Bank
Germany
$262K -$357K -6,008 -52%
Mirae Asset Global Investments
90
Mirae Asset Global Investments
South Korea
$255K +$91.4K +1,537 +41%
State of Tennessee, Department of Treasury
91
State of Tennessee, Department of Treasury
Tennessee
$237K +$13.4K +225 +5%
State Board of Administration of Florida Retirement System
92
State Board of Administration of Florida Retirement System
Florida
$235K – – –
Janus Henderson Group
93
Janus Henderson Group
United Kingdom
$234K +$145K +2,436 +100%
Manulife (Manufacturers Life Insurance)
94
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$232K -$9.76K -164 -3%
VEA
95
Virtus ETF Advisers
New York
$230K +$4.17K +70 +1%
Ensign Peak Advisors
96
Ensign Peak Advisors
Utah
$220K – – –
IC
97
IEQ Capital
California
$219K -$17.8K -300 -6%
US Bancorp
98
US Bancorp
Minnesota
$215K -$9.99K -168 -4%
II
99
Inspire Investing
Idaho
$207K +$35.2K +592 +16%
CIC
100
Cornercap Investment Counsel
Georgia
$206K +$81K +1,361 +46%
2 3
4
5 6

NKTR Hedge Fund Activity: Q3 2022 in Review

230 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q3 2022, worth a combined $561M — down 19% from $693M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new NKTR positions and 25 closed out — a net gain of 5 holders — while 70 added to existing stakes and 74 trimmed.

The largest buyer was BlackRock, adding an estimated $13.8M. The largest seller was First Trust Advisors, exiting entirely with an estimated $29.8M sold.

  • 230 institutional investors held Nektar Therapeutics (NKTR) as of Q3 2022, up from 227 in Q2 2022.
  • Funds reported $561M of Nektar Therapeutics stock for Q3 2022, down 19% quarter-over-quarter.
  • 30 funds opened new Nektar Therapeutics positions in Q3 2022 and 25 closed out, a net change of +5 holders.
  • The largest Nektar Therapeutics buyer in Q3 2022 was BlackRock, an estimated $13.8M added.
  • The largest Nektar Therapeutics seller in Q3 2022 was First Trust Advisors, an estimated $29.8M sold.

Based on aggregated 13F filings for Q3 2022.